Huntsman treats first patients in Ac-225 RYZ401 trial
The Phase 1 first-in-human trial is evaluating RYZ401, an Ac-225-labeled radiopharmaceutical targeting somatostatin receptors in neuroendocrine tumors and other solid tumors.
Huntsman Cancer Institute at the University of Utah has treated the first 3 patients in a Phase 1 first-in-human clinical trial of RYZ401, an investigational actinium-225-labeled radiopharmaceutical therapy.
The study is evaluating RYZ401 in patients with neuroendocrine tumors and other solid tumors that express somatostatin receptors. RayzeBio, a Bristol Myers Squibb company, is sponsoring the trial.
RYZ401 combines a peptide targeting somatostatin receptors with Ac-225, an alpha-emitting isotope. The approach is intended to deliver radiation directly to cancer cells over a short distance, according to Huntsman Cancer Institute.
The trial is designed as a dose-escalation and dose-expansion study. ClinicalTrials.gov lists the study as recruiting and describes it as evaluating RYZ401 in patients with solid tumors expressing somatostatin receptors.
Study objectives include assessing safety, tolerability, and early efficacy. The trial is also intended to support selection of a recommended Phase 2 dose and treatment regimen, according to RayzeBio’s study description.
Heloisa Soares, MD, PhD, is leading the study at Huntsman Cancer Institute. She is medical director of theranostics at Huntsman and associate professor of internal medicine at the University of Utah.
“This study represents an important step toward developing the next generation of targeted radiopharmaceutical therapies,” Soares said.
Sources
- Study of RYZ401 in Subjects With Solid Tumors Expressing Somatostatin Receptors. Peer-reviewed study
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pediatric ED imaging gaps persist by race and insurance status
A cohort study of 857,034 pediatric ED visits found that stronger hospital pediatric capability was not associated with narrower imaging-use differences by race, ethnicity, or insurance status.
Chest X-ray AI study exposes lung cancer detection gaps
A head-to-head study of 7 commercial AI devices found sensitivity ranged from 20.8% to 77.8% for lung cancer detection on chest X-rays.
MRI radiomics score flags aggressive colorectal cancer subtype
The multicenter study found an MRI-based machine-learning radiomics score predicted CMS4 colorectal cancer and stratified recurrent metastasis risk.
Contrast tied to higher AKI risk in neonatal ICU study
The retrospective study found higher acute kidney injury rates in neonates exposed to iodinated contrast media, although most cases were stage 1.
Quantum BioPharma reports early PET tracer signal in MS study
The ongoing MGH study is evaluating [18F]3F4AP PET imaging for demyelinated neurons with intact axons in patients with multiple sclerosis.
PSA screening review finds fewer deaths, more diagnoses
The updated review found PSA screening likely reduces prostate cancer deaths, but evidence remains unclear for newer screening strategies combining PSA, kallikrein testing, and MRI.
Stage 4 breast cancer diagnoses rise over decade
A cohort study of 761,471 people found de novo stage 4 breast cancer incidence increased by 1.2% per year from 2010 to 2021.
SIR backs genicular artery embolization for knee osteoarthritis
The Society of Interventional Radiology issued a position statement supporting genicular artery embolization for symptomatic knee osteoarthritis.
Fluoride, lead co-exposure linked to lower youth BMD
Researchers analyzed NHANES data from 2,378 U.S. children and adolescents who underwent DEXA scans from 2013 to 2016.
Stanford project aims to make MR lymphangiography faster
Stanford Medicine received up to $3.9M from ARPA-H to advance MR lymphangiography. Andreas Loening, MD, PhD, will lead work on faster scans, lymphatic-specific contrast agents, and contrast-free flow assessment.
Bayer PET tracer meets cardiac amyloidosis endpoints
Bayer reported positive topline phase 3 REVEAL results for I-124 evuzamitide, an investigational PET/CT radiotracer for suspected cardiac amyloidosis. The study met its sensitivity and specificity endpoints.
14-minute MRx scan maps 20+ brain biomarkers without contrast
University of Illinois researchers developed multiplexed MRI to map more than 20 brain biomarkers in a single scan using standard clinical MRI systems.